What is First Tracks Biotherapeutics, Inc.'s (TRAX) StockRank?

MoatMap's StockRank for First Tracks Biotherapeutics, Inc. (TRAX) is 6/100, with a Strong Sell signal. This is a composite score combining Quality (29), Value (23), and Momentum (23) factor ranks across MoatMap's 20,000+ stock universe.

Does First Tracks Biotherapeutics, Inc. have an economic moat?

First Tracks Biotherapeutics, Inc. (TRAX) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is First Tracks Biotherapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for First Tracks Biotherapeutics, Inc. (TRAX) is Strong Sell, based on a StockRank of 6/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is First Tracks Biotherapeutics, Inc. in?

First Tracks Biotherapeutics, Inc. (TRAX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

TRAX

Strong Sell

First Tracks Biotherapeutics, Inc. · Healthcare · United States · $1.5B · Avg Vol: $29M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-41.8%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

First Tracks Biotherapeutics is a clinical-stage biotechnology company dedicated to developing novel immunotherapies for the treatment of cancer and autoimmune diseases. The company's proprietary platform focuses on engineering highly selective monoclonal antibodies and cell therapies designed to modulate the immune microenvironment. Its competitive moat is anchored by a robust pipeline of early-stage candidates and proprietary intellectual property in immune-oncology pathways.

FINANCIAL SUMMARY (USD)

Year	2023	2024	TTM	2026E	2027E	Fwd CAGR
Revenue	0	0	—	—	—	—
EPS	-3.05	-4.71	-4.71	-4.06	-3.66	—
Shares	34.7M	34.7M	35.7M	—	—	—
Debt	17.8M	16.0M	4.3M	—	—	—
Equity	409.8M	391.6M	—	—	—	—
Op CF	-93.0M	-125.8M	-123.8M	—	—	—
Inv CF	144.8M	95.4M	—	—	—	—
Fin CF	-87.1M	117.5M	—	—	—	—

Loading 1Y...

PRICE (1Y)+13.5%

SMA 50SMA 200

$41.86

RSI (14)

32.6

SCORE BREAKDOWN

Quality

ROIC

-44.6%18.3

ROE

-41.8%21.8

GP/Assets

-31.6%3.0

Op. Margin

0.0%40.1

FCF/Assets

-28.6%15.6

Piotroski

322.6

Int. Cover

—N/A

D/E Ratio

0.03x77.4

Current Ratio

14.28x92.0

Value

P/E (TTM)

—N/A

EV/EBITDA

-8.4x25.0

P/FCF

—N/A

P/B

9.3x12.8

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

—N/A

RS 6M

—N/A

SMA 50/200

—N/A

EPS Rev 4W

-13.1%8.3

EPS Rev 12W

-15.4%9.4

EPS Improve

+22%36.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.5B

P/E (Forward)

-12.1x

Gross Margin

—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TRAX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
TRAX	First Tracks Biotherapeutics, Inc.(you)	$1.5B	6	Strong Sell
LTGO	Latigo Biotherapeutics, Inc.	$1.5B	8	Strong Sell
MAZE	Maze Therapeutics, Inc.	$1.5B	9	Strong Sell
SNDX	Syndax Pharmaceuticals, Inc.	$1.7B	7	Strong Sell
TYRA	Tyra Biosciences, Inc.	$1.5B	10	Strong Sell
AVLN	Avalyn Pharma Inc.	$1.5B	11	Strong Sell
SPTX	Seaport Therapeutics, Inc.	$1.3B	9	Strong Sell
GENB	Generate Biomedicines, Inc.	$2.0B	6	Strong Sell
NTLA	Intellia Therapeutics, Inc.	$1.8B	8	Strong Sell
SANA	Sana Biotechnology, Inc.	$1.2B	8	Strong Sell

Peer medians: ROE -25.6% · P/E 28.9x · Gross margin 58.7%

First Tracks Biotherapeutics, Inc. (TRAX): Stock Score Summary

First Tracks Biotherapeutics, Inc. (TRAX) has a MoatMap StockRank of 6/100 based on Quality (29/100), Value (23/100), and Momentum (23/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$41.86
Market Cap	$1.5B
P/E (Forward)	-12.06
Price/Book	9.26
Return on Equity	-41.8%
Return on Invested Capital	-44.6%
Debt/Equity	0.03x
Operating Margin	0.0%
Free Cash Flow	$-126M

First Tracks Biotherapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is First Tracks Biotherapeutics, Inc.’s (TRAX) StockRank?: MoatMap’s StockRank for First Tracks Biotherapeutics, Inc. (TRAX) is 6/100, with a Strong Sell signal. It is a composite of Quality (29), Value (23), and Momentum (23) factor ranks across MoatMap’s 20,000+ stock universe.
Does First Tracks Biotherapeutics, Inc. have an economic moat?: First Tracks Biotherapeutics, Inc. (TRAX) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is First Tracks Biotherapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for First Tracks Biotherapeutics, Inc. (TRAX) is Strong Sell, based on a StockRank of 6/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is First Tracks Biotherapeutics, Inc. in?: First Tracks Biotherapeutics, Inc. (TRAX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).